Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human double-blind placebo-controlled dose-escalation study of KCP506 in healthy adults
NL-OMON55203Phase 1Completed
- Sponsor
- Kineta Chronic Pain
- Start
- Oct 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of KCP-506 in chronic pain (13 arms), sponsored by Kineta Chronic Pain. Primary endpoints: Safety and tolerability after single ascending doses and Safety and tolerability after multiple ascending doses. Started Oct 2020; status: completed.
02
Drugs
KCP-506
03
Conditions
chronic pain
Beyond the preview
Go deeper on NL-OMON55203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55203.